Table 1.

Details of candidate vaccines and trials^1,5,29,45

Trial	Platforms	Schedule (days)	ROA	Dose	Adjuvant	Excipients  a	Developers	Phase	Efficacy (%)	VAEs	Storage
Com-Cov2 (UK)	VVnr	0–28	IM	5x10^10vp (0.5 mL)	-	Polysorbate 80	AstraZeneca and University of Oxfordb	4	76–100	Tenderness, pain, warmth, redness, itching, swelling	Regular fridge
	mRNA	0–21	IM	30 μg (0.3 mL)	-	PEG	Pfizer/BioNTech and Fosun Pharmab	4	95	Chills, headache, pain, tiredness, redness, swelling	–70°C
	mRNA	0–28	IM	0.10 mg mRNA(0.5 ml)	-	PEG	Moderna and NIAID	4	86	Similar to Pfizer vaccine	–20 °C
	PS	0–21	IM	5 μg SARS-CoV-2 rS + 50 μg Matrix-M1 adjuvant (0.5 ml)	Matrix M	PEG	Novavax	3	96.4–100	None reported	Regular fridge

IM: intramuscular; NIAID: National Institute of Allergy and Infectious Diseases; PEG: polyethylene glycol; PS: protein subunit; ROA: route of administration; VAE: vaccine adverse events; VP: viral particles; VVnr: non-replicating viral vectors; WFI: water for injection.

^aImportant excipient.

^bSame in CombivacS trial (Spain)¹⁵.